NorthWest Biotherapeutics Inc (NWBO)

[trocprofit]

Even if they get manufacturing cert for Sawston, capacity doesn't equate to revenues unless someone pays. And, in this case it's out of pocket. Tough Ticket. And, those investigating compassionate care for a GBM will also look for topline release, if they have time. Even if they got to full capacity with patients able to pay, $120 million per year annual revenue and maybe $50 million profit is $.05/share. So, we would essentially be properly valued at these levels as a "growth" company. Topline is still all that matters.